Sickle cell disease in the United States: Looking back and forward at 100 years of progress in management and survival

American Journal of Hematology

Volumn 85, Issue 5, 2010, Pages 346-353

  Prabhakar, Hari ^a   Haywood Jr , Carlton ^b   Molokie, Robert ^c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; CANCER SURVIVAL; CAUSE OF DEATH; HUMAN; MEDICAL RESEARCH; MORTALITY; NEWBORN SCREENING; PRIORITY JOURNAL; REVIEW; SICKLE CELL ANEMIA; UNITED STATES; VACCINATION;

ADOLESCENT; ADULT; ANEMIA, SICKLE CELL; ANTISICKLING AGENTS; CHILD; CHILD, PRESCHOOL; HEALTH POLICY; HUMANS; INFANT; MASS SCREENING; MIDDLE AGED; PATIENT RIGHTS; SURVIVAL ANALYSIS; UNITED STATES; YOUNG ADULT;

EID: 77951619147     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.21676     Document Type: Review

References (95)

1. Herrick J. Peculiar elongated and sickle-shaped red blood corpuscles in a case of severe anemia. Arch Intern Med 1910;6:517-521.
2. Savitt TL. The invisible malady: sickle cell anemia in America, 1910-1970. J Natl Med Assoc 1981;7:739-746.
3. Diggs L, Ahmann D, Bibb J. The incidence and significance of the sickle cell trait. Ann Intern Med 1933;7:769-776.
4. Diggs L, Ching RE. Pathology of sickle cell anemia. South Med J 1934;27:839-845.
5. Johnson CS. Landmark perspective. Sickle cell anemia. JAMA 1985;254:1958-1963.
6. Neel J. The inheritance of sickle cell anemia. Science 1949;110:64-66.
7. Sherman I. The sickling phenomenon, with special reference to the differentiation of sickle cell anemia from sickle cell trait Bull. Johns Hopkins Hospital 1940;67:309-324.
8. Serjeant GR. The emerging understanding of sickle cell disease. Br J Haematol 2001;112:3-18. (Pubitemid 32151142)
9. Manci EA, Culberson DE, Yang YM, et al. Causes of death in sickle cell disease: An autopsy study. Br J Haematol 2003 Oct;123:359-365.
10. Sydenstricker V. Sickle cell anemia. South Med J 1924;17:177-183.
11. Watson J. A study of sickling of young erythrocytes in sickle cell anemia. Blood 1948;3:465-469.
12. Ingram VM. Gene mutations in human haemoglobin: The chemical difference between normal and sickle cell haemoglobin. Nature 1957;180:326-328.
13. Ingram VM. A specific chemical difference between the globins of normal human and sickle-cell anaemia haemoglobin. Nature 1956;178:792-794.
14. Hunt JA, Ingram VM. Abnormal human haemoglobins. II. The chymotryptic digestion of the trypsin-resistant core of haemoglobins A and S. Biochim Biophys Acta 1958;28:546-549.
15. Robinson M.Clinical aspects of sickle cell disease in sickle cell anemia and other hemoglobinopathies. In: Levere R, editor. Sickle Cell Anemia and Other Hemoglobinpathies, 1st ed. New York: Academic Press; 1975. pp 87-112.
16. Powars D, Overturf G, Weiss J, et al. Pneumococcal septicemia in children with sickle cell anemia. Changing trend of survival. JAMA 1981;245:1839-1842.
17. Davis H, Gergen PJ, Moore RM Jr. Geographic differences in mortality of young children with sickle cell disease in the United States. Public Health Rep 1997;112:52-58. (Pubitemid 27053115)
18. Scott RB. Health care priority and sickle cell anemia. JAMA 1970;214:731-734.
19. Wooley J, Peters G. Richard Nixon: Statement on Signing the National Sickle Cell Anemia Control Act. 2009; Available at: http://www.presidency.ucsb. edu/ws/index.php?pid53413. Accessed on: July 13, 2009.
20. Leikin SL, Gallagher D, Kinney TR, et al. Mortality in children and adolescents with sickle cell disease. Cooperative Study of Sickle Cell Disease. Pediatrics 1989;84:500-508. (Pubitemid 19216350)
21. Davis H, Schoendorf KC, Gergen PJ, et al. National trends in the mortality of children with sickle cell disease, 1968 through 1992. Am J Public Health 1997;87:1317-1322.
22. Rogers DW, Clarke JM, Cupidore L, et al. Early deaths in Jamaican children with sickle cell disease. Br Med J 1978;1:1515-1516. (Pubitemid 8376835)
23. Barrett-Connor E. Bacterial infection and sickle cell anemia. An analysis of 250 infections in 166 patients and a review of the literature. Medicine (Baltimore) 1971;50:97-112.
24. Serjeant G, Gueri M. Sickle cell trait and leg ulceration. Br Med J 1970;1:820.
25. Serjeant GR, Ashcroft MT, Serjeant BE. The clinical features of haemoglobin SC disease in Jamaica. Br J Haematol 1973;24:491-501.
26. Serjeant GR, Richards R, Barbor PR, et al. Relatively benign sickle-cell anaemia in 60 patients aged over 30 in the West Indies. Br Med J 1968;3:86-91.
27. Serjeant GR, Serjeant BE, Milner PF. The irreversibly sickled cell; a determinant of haemolysis in sickle cell anaemia. Br J Haematol 1969;17:527-533.
28. Milner PF, Charache S. Life span of carbamylated red cells in sickle cell anemia. J Clin Invest 1973;52:3161-3171.
29. Peterson CM, Graziano JH, De Ciutiis A, et al. Iron metabolism, sickle cell disease, and response to cyanate. Blood 1975;46:583-590.
30. Peterson CM, Lu YS, Herbert JT, et al. Studies with intravenous sodium cyanate in patients with sickle cell anemia. J Pharmacol Exp Ther 1974;189:577-584.
31. Deiderich DA, Trueworthy RC, Gill P, et al. Hematologic and clinical responses in patients with sickle cell anemia after chronic extracorporeal red cell carbamylation. J Clin Invest 1976;58:642-653.
32. Langer EE, Stamatoyannopoulos G, Hlastala MP, et al. Extracorporeal treatment with cyanate in sickle cell disease: Preliminary observations in four patients. J Lab Clin Med 1976;87:462-474.
33. Harkness DR, Roth S. Clinical evaluation of cyanate in sickle cell anemia. Prog Hematol 1975;9:157-184.
34. Desimone J, Heller P, Hall L, Zwiers D. 5-Azacytidine stimulates fetal hemoglobin synthesis in anemic baboons. Proc Natl Acad Sci USA 1982;79:4428-4431. (Pubitemid 12045807)
35. Gaston MH, Verter JI, Woods G, et al. Prophylaxis with oral penicillin in children with sickle cell anemia. A randomized trial. N Engl J Med 1986;314:1593-1599. (Pubitemid 16118215)
36. Gaston MH, Verter J. Sickle cell anaemia trial. Stat Med 1990;9:45-49.discussion 49-51.
37. Emond AM, Collis R, Darvill D, et al. Acute splenic sequestration in homozygous sickle cell DISEASE: Natural history and management. J Pediatr 1985;107:201-206. (Pubitemid 15241908)
38. Vichinsky E, Hurst D, Earles A, et al. Newborn screening for sickle cell disease: Effect on mortality. Pediatrics 1988;81:749-755.
39. National Institutes of Health. 1987; Available at: http://consensus.nih. gov/1987/1987ScreeningSickleHemoglobinopathies061html.htm. Accessed on: October 30, 2009.
40. Sickle Cell Disease Association of America. HRSA Awards More Than $4.4 Million in Grants. 2002; Available at: http://www.sicklecelldisease. org/news/archive/press5.phtml. Accessed on: October 30, 2009.
41. O'Brien KL, Dagan R. The potential indirect effect of conjugate pneumococcal vaccines. Vaccine 2003;21:1815-1825. (Pubitemid 36428771)
42. Adamkiewicz TV, Silk BJ, Howgate J, et al. Effectiveness of the 7-valent pneumococcal conjugate vaccine in children with sickle cell disease in the first decade of life. Pediatrics 2008;121:562-569.
43. Qureshi N, Lubin B, Walters MC. The prevention and management of stroke in sickle cell anaemia. Expert Opin Biol Ther 2006;6:1087-1098. (Pubitemid 44714137)
44. Adams RJ. Lessons from the Stroke Prevention Trial in Sickle Cell Anemia (STOP) study. J Child Neurol 2000;15:344-349.
45. Adams RJ, Brambilla D. Optimizing Primary Stroke Prevention in Sickle Cell Anemia (STOP 2) Trial Investigators. Discontinuing prophylactic transfusions used to prevent stroke in sickle cell disease. N Engl J Med 2005;353:2769-2778.
46. Platt OS, Brambilla DJ, Rosse WF, et al. Mortality in sickle cell disease. Life expectancy and risk factors for early death. N Engl J Med 1994;330:1639-1644. (Pubitemid 124005049)
47. Wierenga KJ, Hambleton IR, Lewis NA. Survival estimates for patients with homozygous sickle-cell disease in Jamaica: A clinic-based population study. Lancet 2001;357:680-683.
48. Prasad R, Hasan S, Castro O, et al. Long-term outcomes in patients with sickle cell disease and frequent vaso-occlusive crises. Am J Med Sci 2003;325:107-109. (Pubitemid 36348614)
49. Platt OS, Thorington BD, Brambilla DJ, et al. Pain in sickle cell disease. Rates and risk factors. N Engl J Med 1991;325:11-16.
50. Farber MD, Koshy M, Kinney TR. Cooperative study of sickle cell disease: Demographic and socioeconomic characteristics of patients and families with sickle cell disease. J Chronic Dis 1985;38:495-505. (Pubitemid 15036755)
51. Charache S. Fetal hemoglobin, sickling, and sickle cell disease. Adv Pediatr 1990;37:1-31.
52. Steinberg MH, Barton F, Castro O, et al. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: Risks and benefits up to 9 years of treatment. JAMA 2003;289:1645-1651. (Pubitemid 37430269)
53. Ballas SK, Barton FB, Waclawiw MA, et al. Hydroxyurea and sickle cell anemia: Effect on quality of life. Health Qual Life Outcomes 2006;4:59.
54. Bakanay SM, Dainer E, Clair B, et al. Mortality in sickle cell patients on hydroxyurea therapy. Blood 2005;105:545-547. (Pubitemid 40070734)
55. Wang WC, Wynn LW, Rogers ZR, et al. A two-year pilot trial of hydroxyurea in very young children with sickle-cell anemia. J Pediatr 2001;139:790-796. (Pubitemid 34014457)
56. Zimmerman SA, Schultz WH, Davis JS, et al. Sustained long-term hematologic efficacy of hydroxyurea at maximum tolerated dose in children with sickle cell disease. Blood 2004;103:2039-2045.
57. Voskaridou E, Christoulas D, Bilalis A, et al. The effect of prolonged administration of hydroxyurea on morbidity and mortality in adult patients with sickle-cell syndromes: Results of a 17-year, single center trial (LaSHS). Blood 2009. Epub ahead of print.
58. Walters MC, Patience M, Leisenring W, et al. Bone marrow transplantation for sickle cell disease. N Engl J Med 1996;335:369-376. (Pubitemid 26257244)
59. Walters MC. Bone marrow transplantation for sickle cell disease: Where do we go from here? J Pediatr Hematol Oncol 1999;21:467-474.
60. Johnson FL, Look AT, Gockerman J, et al. Bone-marrow transplantation in a patient with sickle-cell anemia. N Engl J Med 1984;311:780-783. (Pubitemid 14026230)
61. Walters MC, Patience M, LeisenringW, et al. Barriers to bone marrow transplantation for sickle cell anemia. Biol Blood Marrow Transplant 1996;2:100-104. (Pubitemid 126488201)
62. Bernaudin F, Socie G, Kuentz M, et al. Long-term results of related myeloablative stem-cell transplantation to cure sickle cell disease. Blood 2007;110:2749-2756. (Pubitemid 47523201)
63. Michlitsch JG, Walters MC. Recent advances in bone marrow transplantation in hemoglobinopathies. Curr Mol Med 2008;8:675-689.
64. Hsieh MM, Kang EM, Fitzhugh CD, et al. Allogeneic hematopoietic stem-cell transplantation for sickle cell disease. N Engl J Med 2009;361:2309-2317.
65. Morris CR. Asthma management: Reinventing the wheel in sickle cell disease. Am J Hematol 2009;84:234-241.
66. Boyd JH, Macklin EA, Strunk RC, et al. Asthma is associated with increased mortality in individuals with sickle cell anemia. Haematologica 2007;92:1115-1118. (Pubitemid 350144219)
67. Kato GJ, Gladwin MT. Evolution of novel small-molecule therapeutics targeting sickle cell vasculopathy. JAMA 2008;300:2638-2646.
68. Morris CR. New strategies for the treatment of pulmonary hypertension in sickle cell disease: The rationale for arginine therapy. Treat Respir Med 2006;5:31-45.
69. Pham PT, Pham PC, Wilkinson AH, et al. Renal abnormalities in sickle cell disease. Kidney Int 2000;57:1-8. (Pubitemid 30227747)
70. Ojo AO, Govaerts TC, Schmouder RL, et al. Renal transplantation in end-stage sickle cell nephropathy. Transplantation 1999;67:291-295. (Pubitemid 29066357)
71. Pepke-Zaba J, Higenbottam TW, Dinh-Xuan AT, et al. Inhaled nitric oxide as a cause of selective pulmonary vasodilatation in pulmonary hypertension. Lancet 1991;338:1173-1174.
72. Reiter CD, Wang X, Tanus-Santos JE, et al. Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease. Nat Med 2002;8:1383-1389. (Pubitemid 36019423)
73. Gladwin MT, Machado RF, Barst RJ, et al. Safety and efficacy of sildenafil therapy for doppler-defined pulmonary hypertension in patients with sickle cell disease: Preliminary results of the walk-PHaSST clinical trial (#571). Blood 2009;114.
74. Frenette PS, Atweh GF. Sickle cell disease: Old discoveries, new concepts, and future promise. J Clin Invest 2007;117:850-858.
75. Quinn CT, Rogers ZR, Buchanan GR. Survival of children with sickle cell disease. Blood 2004;103:4023-4027. (Pubitemid 38685339)
76. Powars DR, Chan LS, Hiti A, et al. Outcome of sickle cell anemia: A 4-decade observational study of 1056 patients. Medicine (Baltimore) 2005;84:363-376. (Pubitemid 41668935)
77. Raghupathy R, Billett HH. Promising therapies in sickle cell disease. Cardiovasc Hematol Disord Drug Targets 2009;9:1-8.
78. Wright K, Adeosum O. Barriers to effective pain management in sickle cell disease. Br J Nurs 2009;18:158-161.
79. Stinson J, Naser B. Pain management in children with sickle cell disease. Paediatr Drugs 2003;5:229-241. (Pubitemid 36469931)
80. Dampier C, Ely E, Brodecki D, et al. Home management of pain in sickle cell disease: A daily diary study in children and adolescents. J Pediatr Hematol Oncol 2002;24:643-647. (Pubitemid 35285103)
81. Smith WR, Bovbjerg VE, Penberthy LT, et al. Understanding pain and improving management of sickle cell disease: The PiSCES study. J Natl Med Assoc 2005;97:183-193. (Pubitemid 40204537)
82. Smith TJ, Coyne PJ, Smith WR, et al. Use of an implantable drug delivery system for refractory chronic sickle cell pain. Am J Hematol 2005;78:153-154.
83. Koch J, Manworren R, Clark L, et al. Pilot study of continuous co-infusion of morphine and naloxone in children with sickle cell pain crisis. Am J Hematol 2008;83:728-731.
84. Telfer PT, Lahoz C, Ali K, et al. Intranasal diamorphine for acute sickle cell pain. Arch Dis Child 2009;94:979-980.
85. Maxwell K, Streetly A, Bevan D. Experiences of hospital care and treatment seeking for pain from sickle cell disease: Qualitative study. BMJ 1999;318:1585-1590. (Pubitemid 29267771)
86. Haywood C Jr, Beach MC, Lanzkron S, et al. A systematic review of barriers and interventions to improve appropriate use of therapies for sickle cell disease. J Natl Med Assoc 2009;101:1022-1033.
87. Murray N, May A. Painful crises in sickle cell disease - Patients' perspectives. BMJ 1988;297:452-454.
88. Bobo L, Miller ST, Smith WR, et al. Health perceptions and medical care opinions of inner-city adults with sickle cell disease or asthma compared with those of their siblings. South Med J 1989;82:9-12. (Pubitemid 19207590)
89. Shelley B, Kramer KD, Nash KB. Sickle cell mutual assistance groups and the health services delivery system. J Health Soc Policy 1994;5:243-259. (Pubitemid 24363198)
90. Butler DJ, Beltran LR. Functions of an adult sickle cell group: Education, task orientation, and support. Health Soc Work 1993;18:49-56.
91. Alleyne J, Thomas VJ. The management of sickle cell crisis pain as experienced by patients and their carers. J Adv Nurs 1994;19:725-732.
92. Olney RS. Preventing morbidity and mortality from sickle cell disease. A public health perspective. Am J Prev Med 1999;16:116-121.
93. Hawkins MR, Diehl-Svrjcek B, Dunbar LJ. Caring for children with special healthcare needs in the managed care environment. Lippincotts Case Manag 2006;11:216-223.
94. Jenerette CM, Murdaugh C. Testing the theory of self-care management for sickle cell disease. Res Nurs Health 2008;31:355-369.
95. Nabel EG, Shurin SB. A recommitment to sickle cell disease research. Blood 2008;111:4852-4853.